Skip to content

Effects of phased application of artificial intelligence-assisted polyp diagnosis system on independent colonoscopy performance of endoscopists: a multicenter randomized controlled trial

Effects of phased application of artificial intelligence-assisted polyp diagnosis system on independent colonoscopy performance of endoscopists: a multicenter randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045262
Enrollment
Unknown
Registered
2021-04-10
Start date
2021-04-18
Completion date
Unknown
Last updated
2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intestinal polyps

Interventions

Assisted Group:Apply real - time artificial intelligence assisted colonoscopy training system to colonoscopy examination
Unassisted Group:Apply no real - time artificial intelligence assisted colonoscopy training system to colonoscopy examination

Sponsors

Drum Tower Hospital affiliated to Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 45 and 75 years; 2.Continuous subjects undergoing colonoscopy in our center; 3.Use 3-4 L laxatives, defoaming agent, and adjuvant for intestinal preparation according to the guidelines; 4.Signing the Informed Consent.

Exclusion criteria

Exclusion criteria: 1.Patients with highly suspected inflammatory bowel disease, colon cancer, or colon polyposis; 2.People with a history of inflammatory bowel disease, colon cancer, or colon polyps; 3.Tumor subjects who have previously undergone colonoscopy, colon surgery, other colorectal examinations (including surgical polypectomy, mucosectomy, mucosal dissection, etc.) or who are undergoing radiotherapy or chemotherapy; 4.Those who cannot tolerate intestinal preparation or have contraindication to biopsy; 5.Patients taking antiplatelet drugs such as aspirin, clopidogrel, prapogrel, ticagrelor, anticoagulants such as warfarin and heparin, direct oral anticoagulants such as dabigatrun, rivaroxaban, apixaban and edoxaban, failing to discontinue medication, or existing coagulation disorders (platelet count = 1.5); 6.A history of acute myocardial infarction (within 6 months);Have mental illness or symptoms that may make it difficult to participate in the trial;Active bacterial or fungal infection;Poor control of hypertension;Respiratory diseases requiring continuous oxygen treatment;Dialysis; Patients with other serious heart, lung, liver or renal insufficiency diseases or grade IV of American College of Anesthesiologists; 7.Pregnancy or breastfeeding; 8.The total score of the intestinal preparation Boston scale was < 6.

Design outcomes

Primary

MeasureTime frame
adenoma detection rate (ADR);

Secondary

MeasureTime frame
polyp detection rate (PDR);

Countries

China

Contacts

Public ContactZou Xiaoping

Drum Tower Hospital affiliated to Nanjing University Medical School

zouxiaoping795@hotmail.com+86 137770771661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026